| Literature DB >> 34418353 |
Shanu Jain1, Luiz F Barella2, Jürgen Wess2, Marc L Reitman3, Kenneth A Jacobson4.
Abstract
Hepatic insulin resistance (IR) and enhanced hepatic glucose production (HGP) are key features of type 2 diabetes (T2D), contributing to fasting hyperglycemia. Adenosine receptors (ARs) are G protein-coupled and expressed in hepatocytes. Here, we explored the role of hepatic Gi/o-coupled A1AR on insulin resistance and glucose fluxes associated with obesity. We generated a mouse model with hepatocyte-specific deletion of A1AR (A1LΔ/Δ), which was compared with whole body knockout of A1AR or A1AR/A3AR (both Gi-coupled). Selective deletion of hepatic A1AR resulted in a modest improvement in insulin sensitivity. In addition, HFD A1LΔ/Δ mice showed decreased fasting glucose levels. Hyperinsulinemic-euglycemic clamp studies demonstrated enhanced insulin sensitivity with no change in HGP in HFD A1LΔ/Δ mice. Similar to A1LΔ/Δ, fasting blood glucose levels were significantly reduced in whole body A1Δ/Δ and A1Δ/ΔA3Δ/Δ compared to wild-type mice. Taken together, our data support the concept that blocking hepatic A1AR may decrease fasting blood glucose levels without directly affecting hepatocyte glucose metabolism and insulin sensitivity. Published by Elsevier Inc.Entities:
Keywords: Adenosine; Diabetes; G protein-coupled receptor; Glucose metabolism; Liver; Obesity
Mesh:
Substances:
Year: 2021 PMID: 34418353 PMCID: PMC8478863 DOI: 10.1016/j.bcp.2021.114739
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 6.100